He completed a fellowship in Interventional Neuropsychiatry and Neuromodulation at Massachusetts General Hospital, bringing extensive expertise to the management of treatment-resistant mental health ...

Following a complete response letter last year, Satsuma Pharmaceuticals Inc. received U.S. FDA approval of dihydroergotamine nasal powder to treat acute migraine with or without aura. Branded Atzumi, ...

The FDA has approved Atzumi (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.

A budget proposal from President Donald Trump’s administration would cut a federal grant that provides $56 million annually ...

Montgomery County is attributing a dramatic decline in drug deaths to efforts to prevent them, including availability of a ...